Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
暂无分享,去创建一个
Jinjuan Wang | Brent L Wood | Xiaojun Qian | B. Wood | S. Riddell | P. Greenberg | J. Pagel | S. Forman | M. Jensen | O. Press | H. Greisman | Stanley R Riddell | Michael C Jensen | Stephen J Forman | Ajay K Gopal | Andrew Raubitschek | A. Raubitschek | Harvey A Greisman | A. Gopal | Philip D Greenberg | Brian G Till | Catherine G Lindgren | John M Pagel | Oliver W Press | Eric Y Chen | Scott E James | Jinjuan Wang | B. Till | Scott E. James | C. Lindgren | Xiaojun Qian | E. Chen | B. Wood
[1] P. Mclaughlin,et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. , 2008, Blood.
[2] M. Sorror,et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Mike Gough,et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.
[4] S. Riddell,et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. , 2007, Human gene therapy.
[5] M. Slovak,et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] D. Porter,et al. Donor leukocyte infusions in myeloid malignancies: new strategies. , 2006, Best practice & research. Clinical haematology.
[7] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[8] J. Sprent,et al. Homeostasis of memory T cells , 2006, Immunological reviews.
[9] C. Klebanoff,et al. CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.
[10] E. Warren,et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. , 2006, Blood.
[11] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Rosenberg,et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.
[13] M. Maris,et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. , 2004, Blood.
[14] J. Trapani,et al. Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer1 , 2004, The Journal of Immunology.
[15] M. Jensen,et al. CD8 immunomagnetic selection and interleukin-15 (IL-15) facilitate the isolation of human CD8+ cytotoxic T-lymphocytes (CTL) genetically engineered to express an anti-CD20 chimeric T-cell receptor (cTCR) , 2004 .
[16] M. Jensen,et al. CD8 immunomagnetic selection and interleukin-15 (IL-15) facilitate the isolation of human CD8+ cytotoxic T-lymphocytes (CTL) genetically engineered to express an anti-CD20 chimeric T-cell receptor (cTCR). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Riddell,et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] P. Mclaughlin,et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Trapani,et al. Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation , 2003, The Journal of Immunology.
[20] S. Larson,et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.
[21] A. Wu,et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. , 2003, Cytotherapy.
[22] J. Thompson,et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Sprent,et al. Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells , 2002, The Journal of experimental medicine.
[24] S. A. Bush,et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. , 2002, Blood.
[25] J. Gribben,et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Y. Kagami,et al. Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab , 2001, International journal of hematology.
[27] B. Wood,et al. T-cell clonality determination using polymerase chain reaction (PCR) amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled PCR products. , 2000, American journal of clinical pathology.
[28] B. Coiffier,et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Slovak,et al. Human T lymphocyte genetic modification with naked DNA. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] L. Gordon,et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[32] B. Freidlin,et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Wu,et al. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Kaminski,et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] T. Reynolds,et al. T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.
[39] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[40] A. Rimm,et al. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity , 1979, Nature.